Serum stability of peptides

Methods in Molecular Biology

Volumn 494, Issue , 2008, Pages 177-186

  Jenssen, Håvard ^a   Aspmo, Stein Ivar ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NOVOZYMES A S   (Denmark)

Author keywords

Peptide degradation; Peptide half life; Peptide serum stability

Indexed keywords

EID: 84934439926     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-419-3_10     Document Type: Review

References (35)

1. Overbye, K.M., and Barrett, J.F. (2005) Antibiotics: where did we go wrong? Drug Discov. Today 10, 45-52.
2. Levy, S.B., and Marshall, B. (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 10(12 Suppl.), S122-129.
3. Gallwitz, B. (2005) New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud. 2, 61-69.
4. Martinez, N.R., Augstein, P., Moustakas, A.K., et al. (2003) Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J. Clin. Invest. 111, 1365-1371.
5. Cohen, I.R. (2002) Peptide therapy for type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia 45, 1468-1474.
6. Raz, I., Elias, D., Avron, A., Tamir, M., Metzger, M., and Cohen, I.R. (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulationwith a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 24, 1749-1753.
7. Myers, L.K., Sakurai, Y., Tang, B., et al. (2002) Peptide-induced suppression of collagen-induced arthritis in HLA-DR1 transgenic mice. Arthritis Rheum. 46, 3369-3377.
8. Lorey, S., Stockel-Maschek, A., Faust, J., et al. (2003) Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites. Eur. J. Biochem. 270, 2147-2156.
9. Vincent, B., Jiracek, J., Noble, F., et al. (1997) Effect of a novel selective and potent phosphinic peptide inhibitor of endopeptidase 3.4.24.16 on neurotensin-induced analgesia and neuronal inactivation. Br. J. Pharmacol. 121, 705-710.
10. Fridkis-Hareli, M., Santambrogio, L., Stern, J.N., Fugger, L., Brosnan, C., and Strominger, J.L. (2002) Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J. Clin. Invest. 109, 1635-1643.
11. Jenssen, H., Hamill, P., and Hancock, R.E.W. (2006) Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511.
12. Watt, P.M. (2006) Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat. Biotechnol. 24, 177-183.
13. Bush, K., Macielag, M., and Weidner-Wells, M. (2004) Taking inventory: antibacterial agents currently at or beyond phase 1. Curr. Opin. Microbiol. 7, 466-476.
14. Ge, Y., MacDonald, D.L., Holroyd, K.J., Thornsberry, C., Wexler, H., and Zasloff, M. (1999) In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43, 782-788.
15. Hoffmann, R., Bulet, P., Urge, L., and Otvos, L., Jr. (1999) Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochim. Biophys. Acta 1426, 459-467.
16. Howl, J., ed. (2005) Peptide Synthesis and Applications. Totowa, NJ: Humana Press.
17. Rekdal, O., Andersen, J., Vorland, L.H., and Svendsen, J.S. (1999) Construction and synthesis of lactoferricin derivatives with enhanced antibacterial activity. J. Pept. Sci. 5, 32-45.
18. Sato, A.K., Viswanathan, M., Kent, R.B., and Wood, C.R. (2006) Therapeutic peptides: technological advances driving peptides into development. Curr. Opin. Biotechnol. 17, 638-642.
19. Landon, L.A., Zou, J., and Deutscher, S.L. (2004) Is phage display technology on target for developing peptide-based cancer drugs? Curr. Drug Discov. Technol. 1, 113-132.
20. Powell, M.F., Stewart, T., Otvos, L, Jr., et al. (1993) Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res. 10, 1268-1273.
21. Otvos, L., Jr., Urge, L., Xiang, Z.Q., et al. (1994)Glycosylation of synthetic T helper cell epitopic peptides influences their antigenic potency and conformation in a sugar location-specific manner. Biochim. Biophys. Acta 1224, 68-76.
22. Otvos, L., Jr., Cappelletto, B., Varga, I., et al. (1996) The effects of post-translational side-chain modifications on the stimulatory activity, serum stability and conformation of synthetic peptides carrying T helper cell epitopes. Biochim. Biophys. Acta 1313, 11-19.
23. Veronese, F.M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451-1458.
24. Werle, M., and Bernkop-Schnurch, A. (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30, 351-367.
25. Leger, R., Thibaudeau, K., Robitaille, M., et al. (2004) Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg. Med. Chem. Lett. 14, 4395-4398.
26. Dumont, J.A., Low, S.C., Peters, R.T., and Bitonti, A.J. (2006) Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20, 151-160.
27. Murillo, L., Piot, J.M., Coitoux, C., and Fruitier-Arnaudin, I. (2006) Brain processing of hemorphin-7 peptides in various subcellular fractions from rats. Peptides 27, 3331-3340.
28. McDermott, J.R., Smith, A.I., Biggins, J.A., Hardy, J.A., Dodd, P.R., and Edwardson, J.A. (1981) Degradation of luteinizing hormone-releasing hormone by serum and plasma in vitro. Regul. Pept. 2, 69-79.
29. Walter, R., Neidle, A., and Marks, N. (1975) Significant differences in the degradation of pro-leu-gly-NH2 by human serum and that of other species (38484). Proc. Soc. Exp. Biol. Med. 148, 98-103.
30. Springer, C.J., Eberlein, G.A., Eysselein, V.E., Schaeffer, M., Goebell, H., and Calam, J. (1991) Accelerated in vitro degradation of CCK-58 in blood and plasma of patients with acute pancreatitis. Clin Chim Acta. 198, 245-253.
31. White, N., Griffiths, E.C., Jeffcoate, S.L., Milner, R.D.G., Preece, M.A. (1980) Agerelated changes in the degradation of thyrotrophin releasing hormone by human and rat serum. J. Endocrin. 86, 397-402.
32. Frohman, L.A., Downs, T.R., Williams, T.C., Heimer, E.P., Pan, Y.C., and Felix, A.M. (1986) Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J. Clin. Invest. 78, 906-913.
33. Wroblewski, V.J. (1991) Mechanism of deiodination of 125I-human growth hormone in vivo. Relevance to the study of protein disposition. Biochem. Pharmacol. 42, 889-897.
34. Cudic, M., Lockatell, C.V., Johnson, D.E., and Otvos, L., Jr. (2003) In vitro and in vivo activity of an antibacterial peptide analog against uropathogens. Peptides 24, 807-820.
35. Otvos, L., Jr., Snyder, C., Condie, B., Bulet, P., and Wade, J.D. (2005) Chimeric antimicrobial peptides exhibit multiple modes of action. Int. J. Pept. Res. Ther. 11, 29-42.